Trial Profile
A Phase 4, Open-Label, Non-randomized, Multicenter Study to Evaluate Safety and Efficacy of Intravenous Administration of OPTISON for Contrast- Enhanced Echocardiography in Pediatric Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Perflutren (Primary)
- Indications Left ventricular dysfunction
- Focus Diagnostic use
- Sponsors GE Healthcare
- 22 Jun 2023 Status changed from recruiting to completed.
- 23 Jan 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 23 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.